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ABSTRACT
The therapeutic potential of differentiation therapy for glioblastoma will depend on the robustness and
stability of the differentiated state. We recently reported several obstacles to bone morphogenetic protein
(BMP)-induced differentiation therapy. Improved understanding of the mechanisms that tumor cells use
to escape differentiation commitment is urgently needed. KEYWORDS
Astrocyte; BMP;
differentiation; DNA
methylation; epigenetics;
Glioblastoma; neural stem
cell; oligodendrocyte
It is well established that many solid cancers have complex his-
tology reminiscent of tissues.1 Cellular phenotypic heterogene-
ity within tumors may be explained by a hierarchy of
differentiation comparable to normal tissues, with only subsets
of stem cell-like cells being capable of long-term self-renewal.2
This idea was ﬁrst proposed in the 1960s in seminal studies
from Pierce and co-workers, who proposed that human tumors
may be caricatures of normal embryogenesis. This raises the
prospect that signals promoting cell differentiation (i.e., the
acquisition of specialized cellular functions) would be effective
at driving malignant cells to a less aggressive, and ideally post-
mitotic, state. Thus, differentiation therapy for human cancers
has long had a seductive appeal given the possibilities for limit-
ing tumor growth without the pervasive damage to healthy tis-
sues that is a feature of many chemotherapies.
Glioblastoma multiforme (GBM) is an aggressive primary
brain cancer that is driven by cells with neural stem cell charac-
teristics. Bone morphogenetic protein (BMP) signaling is
known to trigger cell cycle exit and astrocyte differentiation in
GBM stem cells3 and might therefore be useful as a differentia-
tion therapy. However, it has remained unclear whether BMP
can drive GBM stem cells to undergo terminal differentiation
and permanent cell cycle arrest. Also, the nature, dynamics,
and stability of epigenetic changes that accompany GBM stem
cell differentiation have not previously been deﬁned. In a recent
study we compared genome-wide changes in transcriptional,
DNA methylation, and chromatin accessibility patterns in dif-
ferentiating GBM-derived neural stem (GNS) cells and geneti-
cally normal neural stem (NS) cell controls to assess the
stability of the differentiated state.4 Such studies are important
to understand the potential barriers to implementation of suc-
cessful differentiation therapy for GBM.
We explored BMP4-induced cell cycle exit and concomitant
upregulation of astrocyte differentiation markers (glial ﬁbrillary
acidic protein [GFAP] and aquaporin 4 [AQP4]), across a large
panel of different primary patient GBM stem cell lines. It was
immediately apparent that many cultures fail to fully respond
to the cytostatic inﬂuence of BMP. Many patients will therefore
possess tumor stem cells that fail to respond at all to BMP. Per-
haps more importantly, even in those cultures where cells were
driven out of cycle, we found that DNA methylation was
incomplete and/or occurred with delayed kinetics compared to
normal NS cells. Likely as a result of this, these non-cycling
and overtly differentiated astrocytes or oligodendrocyte-like
cells could readily re-enter the cell cycle when challenged with
growth factors, and rapid downregulation of differentiation
markers ensued. This suggests that cells fail to achieve differen-
tiation commitment and remain vulnerable to de-differentia-
tion (Fig. 1). Thus, although GBM stem cells can engage in
programs of differentiation, BMP signaling and/or growth fac-
tor withdrawal are not sufﬁcient to drive terminal cell cycle
arrest.
Chromatin accessibility mapping (ATAC-Seq) revealed that
loci that failed to change in response to BMP were enriched in
Sry-related high-mobility-group box (SOX) transcription fac-
tor-binding motifs. Thus, increased activity or levels of SOX
transcription factors may therefore be part of the restriction on
differentiation commitment. It seems that while GBM stem
cells can undergo overt morphologic and phenotypic changes
indicative of differentiation, they remain immature or partially
differentiated. This is clearly highly undesirable, as tumor cells
need to be eradicated or permanently driven out of cycle to
avoid the risks of further epigenetic and genetic selection for
the proliferative stem cell state.
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A caveat of our studies is that our assays were based on cell
cultures. We also challenged cells to de-differentiate through
delivery of a supraphysiological level of growth factors, and it is
possible that in vivo tumor cells would not encounter such sig-
nals and could remain dormant. However, a latent capacity for
dedifferentiation simply by exposure to growth factors has to
be concerning for any proposed differentiation therapy. Fur-
thermore, astrocytes and oligodendrocytes have a long lifespan,
and therefore any differentiation therapy for GBM needs to
account for the fact that the cells will remain long term.
Recently, we have also noted that a differentiation-resistant
clone characterized by neuroﬁbromin 1 (NF1) deletion was
enriched in one of the cell lines during BMP-induced differenti-
ation (unpublished observation). NF1 is an important negative
regulator of the Ras signal transduction pathway and NF1 gene
mutations and deletions are frequent in GBM, especially within
the mesenchymal subgroup.5 Genetic selection of differentia-
tion-resistant subclones is therefore yet another hurdle that
should be anticipated in any clinical design.
We noted unexpectedly slow kinetics of changes in DNA
methylation once cells had engaged in astrocyte differentiation
for both normal NS cells and subsets of responsive GNS cells.
This contrasts with the rapid accumulation of changes that
occur in hematopoietic stem cells. One could speculate that the
urgent and demanding requirements and turnover within the
hematopoietic system necessitate rapid and synchronous deci-
sion making, whereas the time course of development and
acquisition of critical specialized function in the nervous sys-
tem occurs over a much longer time frame. Suva et al. recently
described a set of speciﬁc transcription factors capable of
reprogramming non-tumorigenic serum differentiated GBM
cells (proneural subgroup) into stem-like tumor-propagating
cells.6 However, the nature of the speciﬁc inductive signals in
serum are that limited to tumor initiation in contrast to BMP-
induced differentiation and whether these ﬁndings are limited
to subsets of GBM stem cell cultures remain unclear.7
To summarize, while it is clear that GBM stem cells can
undergo differentiation, it is less clear whether they are able to
undergo stable differentiation commitment and terminal cell
cycle arrest. Clinical translation of BMP-based differentiation
therapies may therefore be difﬁcult. First, there are clear differ-
ential responses between cell lines and the same is expected in
patients. Second, induction is rapid but the methylation
changes are slow and require long exposure. Third, the
acquired alterations are not permanent and there is the possi-
bility of reversion, de-differentiation, or selection of differentia-
tion-resistant clones. Clearly, tackling these obstacles up front
will be a major challenge in the design of differentiation thera-
pies. Improved understanding of the mechanisms by which
tumor cells evade differentiation commitment is necessary for
implementation of differentiation therapy for GBM.
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